Ascendis Pharma

Eiger Biopharmaceuticals is a research-driven biopharmaceutical company based in Palo Alto, CA. The company focuses on developing innovative therapies for serious diseases with unmet medical needs. Utilizing cutting-edge technology and scientific expertise, Eiger Biopharmaceuticals is dedicated to advancing novel treatments to improve patient outcomes and quality of life. Generated from their business information

ARCA biopharma, Inc., is dedicated to developing and commercializing genetically targeted therapies for heart failure and other cardiovascular disease. The company's lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. The Company s second compound in development, NU172, is a direct thrombin inhibitor that has completed Phase 1b development for use as a potential short-acting anticoagulant during medical or surgical procedures.

Cantabio Pharmaceuticals Inc, based in East Palo Alto, CA, is a research-focused company dedicated to developing innovative disease modifying therapeutics for neurodegeneration and metabolic conditions. Their scientific approach involves reducing the harmful effects of biochemical stress and targeting intrinsically disordered proteins to prevent and slow the progression of diseases such as Alzheimer's and Parkinson's. With a strategic integration of therapeutic focus, biophysics, and novel drug discovery technologies, Cantabio Pharmaceuticals aims to tackle the challenges posed by these debilitating conditions. Their work has been recognized by the World Economic Forum as a Top 10 World Changing Technology, and they have been awarded grants by The Michael J. Fox Foundation for their groundbreaking research. Through their commitment to drug discovery and research, Cantabio Pharmaceuticals strives to make a significant impact in the field of healthcare.Generated from the website